These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17163756)

  • 1. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive.
    Chiosis G; Neckers L
    ACS Chem Biol; 2006 Jun; 1(5):279-84. PubMed ID: 17163756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90: the vulnerable chaperone.
    Chiosis G; Vilenchik M; Kim J; Solit D
    Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors.
    Sreedhar AS; Nardai G; Csermely P
    Immunol Lett; 2004 Mar; 92(1-2):157-61. PubMed ID: 15081540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and application of Hsp90 inhibitors.
    Solit DB; Chiosis G
    Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach for enhancing differential selectivity of drugs to cancer cells.
    Duvvuri M; Konkar S; Hong KH; Blagg BS; Krise JP
    ACS Chem Biol; 2006 Jun; 1(5):309-15. PubMed ID: 17163760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention.
    Ochel HJ; Gademann G
    Onkologie; 2002 Oct; 25(5):466-73. PubMed ID: 12415202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
    Xu W; Neckers L
    Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
    [No Abstract]   [Full Text] [Related]  

  • 12. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 2.
    Searle B; Collins T
    IDrugs; 2007 Dec; 10(12):836-9. PubMed ID: 18041674
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new Hsp90 inhibitors by structure-based virtual screening.
    Hong TJ; Park H; Kim YJ; Jeong JH; Hahn JS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4839-42. PubMed ID: 19560353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells.
    Neckers L; Kern A; Tsutsumi S
    Chem Biol; 2007 Nov; 14(11):1204-6. PubMed ID: 18022558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.